GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (STU:0K4) » Definitions » Purchase Of Business

Akero Therapeutics (STU:0K4) Purchase Of Business : €0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Akero Therapeutics Purchase Of Business?

Akero Therapeutics's purchase of business for the three months ended in Sep. 2024 was €0.00 Mil. It means Akero Therapeutics spent €0.00 Mil on purchasing business. Akero Therapeutics's purchase of business for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Jun. 2024 ), Akero Therapeutics spent the same money on purchasing business in Sep. 2024 (€0.00 Mil).


Akero Therapeutics Purchase Of Business Historical Data

The historical data trend for Akero Therapeutics's Purchase Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akero Therapeutics Purchase Of Business Chart

Akero Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Business
Get a 7-Day Free Trial - - - - -

Akero Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Purchase Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Akero Therapeutics Purchase Of Business Calculation

The amount used to purchase business.

Purchase Of Business for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akero Therapeutics Purchase Of Business Related Terms

Thank you for viewing the detailed overview of Akero Therapeutics's Purchase Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


Akero Therapeutics Business Description

Traded in Other Exchanges
Address
601 Gateway Boulevard, Suite 350, South San Francisco, CA, USA, 94080
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Akero Therapeutics Headlines

No Headlines